mouse mammary carcinoma cell line 4t1 Search Results


4t-1 mouse mammary carcinoma cancer cell line dual-labeled with luciferase and gfp  (Genecopoeia)
95
Genecopoeia 4t-1 mouse mammary carcinoma cancer cell line dual-labeled with luciferase and gfp
4t 1 Mouse Mammary Carcinoma Cancer Cell Line Dual Labeled With Luciferase And Gfp, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4t-1 mouse mammary carcinoma cancer cell line dual-labeled with luciferase and gfp/product/Genecopoeia
Average 95 stars, based on 1 article reviews
4t-1 mouse mammary carcinoma cancer cell line dual-labeled with luciferase and gfp - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
murine breast cancer cell line 4t1  (JCRB Cell Bank)
90
JCRB Cell Bank murine breast cancer cell line 4t1
The combination of C-REV and S-1 treatment leads to stronger regression of murine <t>4T1</t> tumor Fig. 1a: The in vitro sensitivity of 4T1 cells to C-REV with or without 5-FU was determined by MTT assays. Cells were infected with C-REV at various multiplicities of infection (MOIs). The results are shown as means ± SD. Fig. 1b and 1c: Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups (n=8 per group) with equal average tumor volumes among both groups and both flanks. Fig. 1b, Treatment schema: the mice were treated with 10 mg/kg S-1 for 5 consecutive days per week for 2 weeks. C-REV was administered i.t. to mice on day 0, day 2, day 7, and day 9. Fig. 1c, C-REV was injected into the tumor on only one side (referred to as the injected side; the non-injected side is the contralateral side), and tumor sizes on both sides were measured twice a week. Fig. 1c: Tumor growth and Fig. 1d: mouse survival in 4T1 tumor models after treatment. For the evaluation of survival, death event was defined when the total tumor size reached 1500 mm 3 . ANOVA with a post-hoc Tukey test was performed for tumor size evaluation. Survival analysis was performed using the Kaplan–Meier method. The log-rank test was used for statistical comparison of the curves. * p < 0.05, * * p < 0.01, * * * p < 0.001
Murine Breast Cancer Cell Line 4t1, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine breast cancer cell line 4t1/product/JCRB Cell Bank
Average 90 stars, based on 1 article reviews
murine breast cancer cell line 4t1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


The combination of C-REV and S-1 treatment leads to stronger regression of murine 4T1 tumor Fig. 1a: The in vitro sensitivity of 4T1 cells to C-REV with or without 5-FU was determined by MTT assays. Cells were infected with C-REV at various multiplicities of infection (MOIs). The results are shown as means ± SD. Fig. 1b and 1c: Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups (n=8 per group) with equal average tumor volumes among both groups and both flanks. Fig. 1b, Treatment schema: the mice were treated with 10 mg/kg S-1 for 5 consecutive days per week for 2 weeks. C-REV was administered i.t. to mice on day 0, day 2, day 7, and day 9. Fig. 1c, C-REV was injected into the tumor on only one side (referred to as the injected side; the non-injected side is the contralateral side), and tumor sizes on both sides were measured twice a week. Fig. 1c: Tumor growth and Fig. 1d: mouse survival in 4T1 tumor models after treatment. For the evaluation of survival, death event was defined when the total tumor size reached 1500 mm 3 . ANOVA with a post-hoc Tukey test was performed for tumor size evaluation. Survival analysis was performed using the Kaplan–Meier method. The log-rank test was used for statistical comparison of the curves. * p < 0.05, * * p < 0.01, * * * p < 0.001

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: The combination of C-REV and S-1 treatment leads to stronger regression of murine 4T1 tumor Fig. 1a: The in vitro sensitivity of 4T1 cells to C-REV with or without 5-FU was determined by MTT assays. Cells were infected with C-REV at various multiplicities of infection (MOIs). The results are shown as means ± SD. Fig. 1b and 1c: Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups (n=8 per group) with equal average tumor volumes among both groups and both flanks. Fig. 1b, Treatment schema: the mice were treated with 10 mg/kg S-1 for 5 consecutive days per week for 2 weeks. C-REV was administered i.t. to mice on day 0, day 2, day 7, and day 9. Fig. 1c, C-REV was injected into the tumor on only one side (referred to as the injected side; the non-injected side is the contralateral side), and tumor sizes on both sides were measured twice a week. Fig. 1c: Tumor growth and Fig. 1d: mouse survival in 4T1 tumor models after treatment. For the evaluation of survival, death event was defined when the total tumor size reached 1500 mm 3 . ANOVA with a post-hoc Tukey test was performed for tumor size evaluation. Survival analysis was performed using the Kaplan–Meier method. The log-rank test was used for statistical comparison of the curves. * p < 0.05, * * p < 0.01, * * * p < 0.001

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques: In Vitro, Infection, Injection, Comparison

Fractional cell survival (FCS) of 4T1 tumor cells following treatment with 5-FU and C-REV alone or in combination

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: Fractional cell survival (FCS) of 4T1 tumor cells following treatment with 5-FU and C-REV alone or in combination

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques:

C-REV enhances the infiltration of CD3 + CD8 + T cells into tumors and increases IFNγ production by CD3 + CD8 + T cells Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups with an equal average tumor volume among the groups and both flanks. Each group contained three mice. Mice were given S-1 (10 mg/kg) by oral gavage (5 consecutive days, day 0–4) in addition to an intratumoral injection of C-REV (5 × 10 5 PFU) on day 0 and day 2. Tumors were harvested 3 days after the final treatment from both the injected and non-injected sites. Fig. 2a: CD4 + T cells and Fig. 2b: CD8 + T cells, gated from CD45 + CD3 + cells after treatment with C-REV, S-1, and their combination, were analyzed by flow cytometry. Fig. 2c: Tumor-infiltrating lymphocytes were isolated. These cells were stimulated with anti-CD3/anti-CD28 antibody, and intracellular staining of IFNγ was performed. * p < 0.05, * * p < 0.01

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: C-REV enhances the infiltration of CD3 + CD8 + T cells into tumors and increases IFNγ production by CD3 + CD8 + T cells Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups with an equal average tumor volume among the groups and both flanks. Each group contained three mice. Mice were given S-1 (10 mg/kg) by oral gavage (5 consecutive days, day 0–4) in addition to an intratumoral injection of C-REV (5 × 10 5 PFU) on day 0 and day 2. Tumors were harvested 3 days after the final treatment from both the injected and non-injected sites. Fig. 2a: CD4 + T cells and Fig. 2b: CD8 + T cells, gated from CD45 + CD3 + cells after treatment with C-REV, S-1, and their combination, were analyzed by flow cytometry. Fig. 2c: Tumor-infiltrating lymphocytes were isolated. These cells were stimulated with anti-CD3/anti-CD28 antibody, and intracellular staining of IFNγ was performed. * p < 0.05, * * p < 0.01

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques: Injection, Flow Cytometry, Isolation, Staining

C-REV enhances IFNγ production by CD3 + CD8 + T cells in tumor-draining lymph nodes Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups (n=3/group) with an equal average tumor volume among the groups and both flanks. Lymphocytes were harvested 3 days after the final treatment from tumor-draining lymph nodes. Fig. 5a: MDSC gated from CD45 + cells and Fig. 5b: T cells and those gated from CD45 + CD3 + cells were analyzed by flow cytometry after treatment with C-REV, S-1, and their combination. Fig. 5c: T cells isolated from tumor-draining lymph nodes were stimulated with anti-CD3/anti-CD28 antibody, and intracellular staining of IFNγ was performed. * p < 0.05, * * p < 0.01

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: C-REV enhances IFNγ production by CD3 + CD8 + T cells in tumor-draining lymph nodes Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups (n=3/group) with an equal average tumor volume among the groups and both flanks. Lymphocytes were harvested 3 days after the final treatment from tumor-draining lymph nodes. Fig. 5a: MDSC gated from CD45 + cells and Fig. 5b: T cells and those gated from CD45 + CD3 + cells were analyzed by flow cytometry after treatment with C-REV, S-1, and their combination. Fig. 5c: T cells isolated from tumor-draining lymph nodes were stimulated with anti-CD3/anti-CD28 antibody, and intracellular staining of IFNγ was performed. * p < 0.05, * * p < 0.01

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques: Flow Cytometry, Isolation, Staining